- Home
- CCCX vs ATAI Comparison
CCCX vs ATAI Comparison
Compare CCCX & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCX
- ATAI
- Stock Information
- Founded
- CCCX 2024
- ATAI 2018
- Country
- CCCX United States
- ATAI Germany
- Employees
- CCCX N/A
- ATAI N/A
- Industry
- CCCX Blank Checks
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- CCCX Finance
- ATAI Health Care
- Exchange
- CCCX Nasdaq
- ATAI Nasdaq
- Market Cap
- CCCX 527.0M
- ATAI 444.7M
- IPO Year
- CCCX 2025
- ATAI 2021
- Fundamental
- Price
- CCCX $10.12
- ATAI $4.60
- Analyst Decision
- CCCX
- ATAI Strong Buy
- Analyst Count
- CCCX 0
- ATAI 3
- Target Price
- CCCX N/A
- ATAI $13.33
- AVG Volume (30 Days)
- CCCX 11.9K
- ATAI 5.8M
- Earning Date
- CCCX 01-01-0001
- ATAI 08-14-2025
- Dividend Yield
- CCCX N/A
- ATAI N/A
- EPS Growth
- CCCX N/A
- ATAI N/A
- EPS
- CCCX 0.14
- ATAI N/A
- Revenue
- CCCX N/A
- ATAI $2,309,000.00
- Revenue This Year
- CCCX N/A
- ATAI $661.36
- Revenue Next Year
- CCCX N/A
- ATAI N/A
- P/E Ratio
- CCCX $269.43
- ATAI N/A
- Revenue Growth
- CCCX N/A
- ATAI 510.85
- 52 Week Low
- CCCX $10.22
- ATAI $1.03
- 52 Week High
- CCCX $10.50
- ATAI $5.34
- Technical
- Relative Strength Index (RSI)
- CCCX N/A
- ATAI 67.07
- Support Level
- CCCX N/A
- ATAI $4.51
- Resistance Level
- CCCX N/A
- ATAI $4.91
- Average True Range (ATR)
- CCCX 0.00
- ATAI 0.36
- MACD
- CCCX 0.00
- ATAI 0.01
- Stochastic Oscillator
- CCCX 0.00
- ATAI 62.55
About CCCX Churchill Capital Corp X Class A Ordinary Shares
Churchill Capital Corp X is a blank check company.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.